top of page
Recent Posts

New clinical study for children with AML aims to kill leukemia cells and minimize cardiac damage

  • OPACC
  • Dec 19, 2016
  • 1 min read

Cooper is leading a new nationwide clinical trial, conducted within the Children's Oncology Group (COG), for children and adolescents with relapsed acute myelogenous leukemia (AML) to test a drug, CPX-351, which has been designed to kill leukemia cells while minimizing damage to the heart.

Comentarios


Archive
Search By Tags
Rama logo.png
cgcg logo.jpg

524 Bayfield Street North
P.O. Box 20005
Barrie, ON L4M 5E9
Canada

info@opacc.org

705-828-7965

  • Wix Facebook page
  • Wix Twitter page
  • Instagram Social Icon
  • YouTube Social  Icon
bottom of page